Note 13 - Segment Information

3 Months Ended

Sep. 30, 2021

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 13. Segment Information:

The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with the impact of partially owned consolidated subsidiaries as well as acquisition accounting related to inventory, amortization of acquisition-related intangible assets and other acquisition-related expenses. The Protein Sciences and Diagnostics and Genomics segments both include consumables, instruments, services and royalty revenue.

The following is financial information relating to the Company's reportable segments (in thousands):

	Quarter Ended
	September 30,
	2021			2020
Net sales:
Protein Sciences	$	197,186		$	154,446
Diagnostics and Genomics		60,985			50,125
Intersegment		(452	)		(372	)
Consolidated net sales	$	257,719		$	204,199
Operating income:
Protein Sciences	$	90,100		$	70,352
Diagnostics and Genomics		7,463			8,674
Segment operating income		97,563			79,026
Costs recognized on sale of acquired inventory		(1,512)			-
Amortization of acquisition related intangible assets		(18,389	)		(15,501	)
Impact of partially owned consolidated subsidiaries		(1,562	)		-
Acquisition related expenses		2,377			(136	)
Stock-based compensation, inclusive of employer taxes		(13,860	)		(13,333	)
Restructuring costs		(1,185	)		-
Corporate general, selling, and administrative expenses		(210	)		(964	)
Consolidated operating income	$	63,222		$	49,092